Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CAO Craig Gracey sold 2,084 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $20.00, for a total value of $41,680.00. Following the sale, the chief accounting officer directly owned 2,941 shares of the company’s stock, valued at $58,820. This represents a 41.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Craig Gracey also recently made the following trade(s):
- On Wednesday, July 1st, Craig Gracey sold 637 shares of Omada Health stock. The shares were sold at an average price of $23.00, for a total transaction of $14,651.00.
- On Tuesday, June 30th, Craig Gracey sold 405 shares of Omada Health stock. The stock was sold at an average price of $22.00, for a total transaction of $8,910.00.
- On Monday, June 29th, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $21.00, for a total transaction of $43,743.00.
- On Wednesday, June 24th, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $19.01, for a total transaction of $39,597.83.
- On Monday, June 22nd, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $18.00, for a total transaction of $37,494.00.
- On Friday, June 12th, Craig Gracey sold 6,894 shares of Omada Health stock. The stock was sold at an average price of $17.42, for a total value of $120,093.48.
Omada Health Stock Down 1.0%
NASDAQ:OMDA opened at $22.39 on Friday. The business’s 50-day simple moving average is $17.16 and its two-hundred day simple moving average is $15.03. Omada Health, Inc. has a 52 week low of $10.28 and a 52 week high of $26.92. The stock has a market cap of $1.33 billion and a PE ratio of -82.93.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on OMDA shares. The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Barclays upped their price objective on Omada Health from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Citizens Jmp lifted their target price on Omada Health from $18.00 to $21.00 and gave the stock a “market outperform” rating in a report on Friday, May 8th. Citigroup restated an “outperform” rating on shares of Omada Health in a report on Friday, May 8th. Finally, Wells Fargo & Company lifted their price objective on shares of Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.91.
Read Our Latest Analysis on OMDA
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in shares of Omada Health in the second quarter worth $32,000. Bellevue Group AG grew its holdings in shares of Omada Health by 0.7% during the third quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock valued at $5,567,000 after buying an additional 1,791 shares during the last quarter. Quarry LP acquired a new position in shares of Omada Health in the 4th quarter valued at $29,000. Barclays PLC raised its stake in Omada Health by 14.6% in the 4th quarter. Barclays PLC now owns 14,850 shares of the company’s stock worth $234,000 after acquiring an additional 1,888 shares during the last quarter. Finally, TD Waterhouse Canada Inc. acquired a new stake in Omada Health during the 4th quarter worth about $32,000.
Omada Health Company Profile
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Further Reading
- Five stocks we like better than Omada Health
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
